Physician profile
Casey E Shaba
NPI 1710181201
$3,403.95
in general payments reported to CMS, 2019-2025
27 companies · $659 in 2025
The $659 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $170 · 2021: $358 · 2022: $606 · 2023: $872 · 2024: $537 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,953 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,952.84 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $817.28 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $425.95 | 2019-2025 | |
| Janssen Biotech, INC. | $401.98 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $283.47 | 2019-2025 | |
| Galderma Laboratories, L.P. | $235.26 | 2021-2025 | Nemluvio, Oracea, Twyneo |
| Amgen INC. | $183.93 | 2023-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $176.35 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $158.67 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $113.29 | 2020-2023 | Adbry |
| Dermavant Sciences, INC. | $106.09 | 2022-2024 | Vtama |
| Ucb, INC. | $90.61 | 2023-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $68.76 | 2019-2025 | |
| Alk-Abello, INC | $44.53 | 2021-2024 | Pre-Pen, Standardized Mite D. Farinae, Alternaria Tenuis |
| Journey Medical Corporation | $38.94 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.58 | 2023 | Arazlo, Jublia, Duobrii |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $30.50 | 2024-2025 | Zoryve |
| Incyte Corporation | $27.93 | 2021 | |
| Lilly USA, LLC | $22.22 | 2024 | Taltz |
| Regeneron Healthcare Solutions, INC. | $19.88 | 2022 | |
| Celgene Corporation | $19.68 | 2019 | |
| Grifols USA, LLC | $18.74 | 2023 | Xembify |
| Epi Health, LLC | $17.35 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.76 | 2025 | Nuzyra |
| Genzyme Corporation | $15.54 | 2021 | |
| Blueprint Medicines Corporation | $12.27 | 2022 | |
| Merck Sharp & Dohme LLC | $11.82 | 2019 | |
| Organon LLC | $9.57 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Shaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.